U.S. emergency approval broadens use of Gilead’s COVID-19 drug remdesivir
WASHINGTON (Reuters) – Gilead Science Inc’s (GILD.O) antiviral drug remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration for COVID-19 on Friday, clearing the way for broader use of the drug in more hospitals around the United States. During a meeting in the Oval Office of the White House with President…